SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (2454)8/28/2007 9:23:04 PM
From: Biotech Jim   of 3158
 
Ian- AKR-501 is an interesting molecule. The uncertainty here is the size of the thrombocytopenia market (those with low platelet levels and hence prone to bleeding disorders). My view is that if added to ribivirIn and pegylated interferon, it should raise platelets and hence allow for further antiviral hep c therapy. GSK has a competing molecule. Other platelet deficiencies could use such a synthetic TPO agonist, and the question here is how large are all these markets. This is a very good deal by MOGN in my mind. Very interesting.

Disclosure: No position in MOGN.

BJ
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News